Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program

INTRODUCTION: Dupilumab is a monoclonal antibody targeting IL-4Rα recently licensed for severe asthma (SA). A Named Patients Program (NPP) was created in Italy before its commercial availability for SA patients with no other available therapeutic options. We aimed to assess the real-world effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Campisi, Raffaele, Crimi, Claudia, Nolasco, Santi, Beghè, Bianca, Antonicelli, Leonardo, Guarnieri, Gabriella, Scichilone, Nicola, Porto, Morena, Macchia, Luigi, Scioscia, Giulia, Foschino Barbaro, Maria Pia, Papi, Alberto, Crimi, Nunzio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167193/
https://www.ncbi.nlm.nih.gov/pubmed/34079295
http://dx.doi.org/10.2147/JAA.S312123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167193/
https://www.ncbi.nlm.nih.gov/pubmed/34079295
http://dx.doi.org/10.2147/JAA.S312123

Ejemplares similares